Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck KGaA's EMD Serono Appeals Court Decision On Collaboration Agreement With Pfizer Inc


Monday, 15 Apr 2013 08:00am EDT 

Merck KGaA announced that a Pennsylvania appellate court recently decided that the collaboration agreement that EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. entered into in July 2002 for the co-promotion of the multiple sclerosis treatment Rebif (interferon beta-1a) extends until December 31, 2015. EMD Serono, which developed Rebif, had contended that the collaboration should end on December 31, 2013, based on the provisions of the agreement governing extension of the term, and had filed a complaint seeking a court declaration to that end. A lower court ruled that the agreement extends through 2015 and the appellate court affirmed that decision. EMD Serono has asked the appellate court to reconsider ruling. Unless the court grants the request on or before June 7, it will be deemed denied. 

Company Quote

65.26
-0.17 -0.26%
4:51am EDT